Abhinav Aggarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abhinav Aggarwal has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ashraf Ahmed
Department of Internal Medicine Yale University School of Medicine, Bridgeport Hospital Bridgeport Connecticut USA
1 shared publication Didien Meyahnwi
Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
1 shared publication- Fabricio Malaguez Webber
Department of Cardiovascular Diseases, University of Miami, FL, USA
1 shared publication - Gilead I. Lancaster
Department of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, CT, USA
1 shared publication Md Mashiul
Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
1 shared publication- Mohamed Badheeb
Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT, USA
1 shared publication
Latest Publications
- Open Access
- 12 April 2024
- Published by ICR Publications LTD in Journal of Heart Valve Disease Innovation
- Vol. 29 (1) , 45-50
Outcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis
Background: Transcatheter edge-to-edge repair of the mitral valve (M-TEER) improves outcomes in patients with chronic severe symptomatic mitral valve regurgitation who are at high risk for surgical mitral valve repair or replacement. This systematic review and meta-analysis aimed to describe the outcomes of M-TEER in patients with moderate-to-severe (stage III; Group 1) chronic kidney diseases (CKD) and end-stage kidney disease (stages IV-V; Group 2) in comparison with those with normal kidney function or mild CKD (stages I-II; Group 3). Methods: A systematic literature search of PubMed, Scopus, and Embase was conducted from inception to December 10th, 2023. The odds ratio (OR) with a 95% confidence interval (CI) was pooled using the random-effects model. Results: We screened 6,090 articles of which 40 citations were reviewed in full texts. Eight cohort observational studies met the eligibility criteria. Group 1 versus Group 3: short-term and long-term mortality were significantly higher in Group 1 [(OR 1.73, CI: 1.30-2.29) and (OR 1.78, CI: 1.38-2.29), respectively]. The shock was significantly higher (OR 1.95, CI: 1.45-2.63), and vascular complications were significantly lower (OR 0.51, CI: 0.26-0.99) in Group 1. The incidence of stroke, cardiac tamponade, or conversion to open surgery did not differ between groups [OR 0.87, CI: 0.34-2.23), (OR 1.52, CI: 0.62-2.75), or (OR 0.53, 95% CI: 0.12-2.24), respectively]. Group 2 versus Group 3: long-term mortality was significantly higher in Group 2 (OR 3.56, CI: 2.53-5.02) without a difference in short-term mortality (OR 4.92, CI: 0.91-26.72) or conversion to open surgery (OR 0.92, CI: 0.45-1.91) between groups. Conclusion: In patients who are undergoing M-TEER, impaired kidney function may be associated with increased odds of mortality in comparison with absence or mild kidney impairment.
- 12 April 2024
- Published by ICR Publications LTD in Journal of Heart Valve Disease Innovation
- Vol. 29 (1) , 45-50
Open AccessOutcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis
Background: Transcatheter edge-to-edge repair of the mitral valve (M-TEER) improves outcomes in patients with chronic severe symptomatic mitral valve regurgitation who are at high risk for surgical mitral valve repair or replacement. This systematic review and meta-analysis aimed to describe the outcomes of M-TEER in patients with moderate-to-severe (stage III; Group 1) chronic kidney diseases (CKD) and end-stage kidney disease (stages IV-V; Group 2) in comparison with those with normal kidney function or mild CKD (stages I-II; Group 3). Methods: A systematic literature search of PubMed, Scopus, and Embase was conducted from inception to December 10th, 2023. The odds ratio (OR) with a 95% confidence interval (CI) was pooled using the random-effects model. Results: We screened 6,090 articles of which 40 citations were reviewed in full texts. Eight cohort observational studies met the eligibility criteria. Group 1 versus Group 3: short-term and long-term mortality were significantly higher in Group 1 [(OR 1.73, CI: 1.30-2.29) and (OR 1.78, CI: 1.38-2.29), respectively]. The shock was significantly higher (OR 1.95, CI: 1.45-2.63), and vascular complications were significantly lower (OR 0.51, CI: 0.26-0.99) in Group 1. The incidence of stroke, cardiac tamponade, or conversion to open surgery did not differ between groups [OR 0.87, CI: 0.34-2.23), (OR 1.52, CI: 0.62-2.75), or (OR 0.53, 95% CI: 0.12-2.24), respectively]. Group 2 versus Group 3: long-term mortality was significantly higher in Group 2 (OR 3.56, CI: 2.53-5.02) without a difference in short-term mortality (OR 4.92, CI: 0.91-26.72) or conversion to open surgery (OR 0.92, CI: 0.45-1.91) between groups. Conclusion: In patients who are undergoing M-TEER, impaired kidney function may be associated with increased odds of mortality in comparison with absence or mild kidney impairment.